Healthcare
Pelthos Therapeutics Inc.(PTHS)
Live Price
Offline$29.00
+7.37% today
1Y Change
+147.86%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $20.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -70.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pelthos Therapeutics Inc. (PTHS) is a Healthcare stock with a market cap of $20.00M and listed on AMEX. The stock last traded around $29.00 and up 147.9% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -70.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -70.2%, free cash flow -291.7% with operating margin -193.1% and ROIC -26.4%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PTHS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-193.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -70.2%, with operating margin around -193.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -4.5% | -0.9% | +0.7% |
2026 Mar 19, 2026 | +28.4% | -9.7% | -1.0% | +0.2% |
2025 Nov 13, 2025 | -691.0% | -3.1% | -16.4% | -33.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTHS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PTHS Max Drawdown
-51.39%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PTHS and SPY.
Company Overview
Pelthos Therapeutics Inc.
New York Stock Exchange American
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
- Leadership
- Scott Plesha
- IPO Date
- Jul 2, 2025
- Employees
- 4
- Street Address
- 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703
- Mailing
- Durham, NC, 27703
- Region
- Durham, NC, US
- Reporting Currency
- USD
- Investor Line
- 877 265 8266
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.0
- Price/Book
- 2.0
Growth
- Revenue
- 0.0%
- EPS
- -70.2%
- Free Cash Flow
- -291.7%
Profitability
- Gross Margin
- 62.6%
- Operating Margin
- -193.1%
- Net Margin
- -257.9%
- ROE
- -200.4%
- ROIC
- -26.4%
Balance Sheet
- Debt/Equity
- 0.90
- Current Ratio
- 2.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.